Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
- PMID: 18927275
- DOI: 10.1158/1078-0432.CCR-07-5287
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
Abstract
Vascular endothelial growth factor (VEGF)-targeted therapy has become an important treatment option for the management of a number of human malignancies. Unfortunately, a significant number of patients do not respond to VEGF-targeted therapy when used as a single agent or in combination with chemotherapy. Furthermore, the duration of benefit from VEGF-targeted therapy can be relatively short (weeks to months). Ultimately, the vast majority of patients who initially respond to therapy will develop resistance. To date, the molecular and cellular mechanisms associated with resistance to VEGF-targeted agents are poorly understood. The mechanisms of action of anti-VEGF therapy are diverse, and it is entirely possible that resistance mechanisms are similarly diverse and depend on the tumor type. A better understanding of these mechanisms will help in the selection of those patients that are more likely to benefit from VEGF-targeted therapy and also provide for the rational development of therapies that circumvent or overcome resistance.
Similar articles
-
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.Mol Cancer Res. 2007 Mar;5(3):203-20. doi: 10.1158/1541-7786.MCR-06-0404. Mol Cancer Res. 2007. PMID: 17374728 Review.
-
VEGF-targeted therapy: mechanisms of anti-tumour activity.Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3. Nat Rev Cancer. 2008. PMID: 18596824 Review.
-
Targeting tumor angiogenesis.Semin Oncol. 2009 Apr;36(2 Suppl 1):S12-9. doi: 10.1053/j.seminoncol.2009.02.002. Semin Oncol. 2009. PMID: 19393831
-
Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy.Immunol Invest. 2007;36(1):3-23. doi: 10.1080/08820130600991794. Immunol Invest. 2007. PMID: 17190647 Review.
-
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.Nat Clin Pract Oncol. 2008 Sep;5(9):521-30. doi: 10.1038/ncponc1161. Epub 2008 Jul 1. Nat Clin Pract Oncol. 2008. PMID: 18594498 Review.
Cited by
-
Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice.Front Oncol. 2021 May 10;11:637823. doi: 10.3389/fonc.2021.637823. eCollection 2021. Front Oncol. 2021. PMID: 34041019 Free PMC article. Review.
-
Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis.Cell Mol Life Sci. 2017 Feb;74(3):393-398. doi: 10.1007/s00018-016-2347-2. Epub 2016 Aug 29. Cell Mol Life Sci. 2017. PMID: 27572288 Free PMC article. Review.
-
Molecular insight of regorafenib treatment for colorectal cancer.Cancer Treat Rev. 2019 Dec;81:101912. doi: 10.1016/j.ctrv.2019.101912. Epub 2019 Oct 28. Cancer Treat Rev. 2019. PMID: 31715423 Free PMC article. Review.
-
Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.BMC Cancer. 2010 Apr 15;10:143. doi: 10.1186/1471-2407-10-143. BMC Cancer. 2010. PMID: 20398289 Free PMC article.
-
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Clin Cancer Res. 2011 Nov 1;17(21):6840-6. doi: 10.1158/1078-0432.CCR-11-0666. Epub 2011 Sep 2. Clin Cancer Res. 2011. PMID: 21890452 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
